Ironwood Investment Management LLC Has $1,040,000 Position in AMAG Pharmaceuticals, Inc. (AMAG)
Ironwood Investment Management LLC cut its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 7.1% during the third quarter, Holdings Channel reports. The institutional investor owned 42,416 shares of the specialty pharmaceutical company’s stock after selling 3,219 shares during the period. Ironwood Investment Management LLC owned about 0.12% of AMAG Pharmaceuticals worth $1,040,000 as of its most recent filing with the SEC.
Other hedge funds have also bought and sold shares of the company. Capstone Asset Management Co. boosted its stake in AMAG Pharmaceuticals by 5.1% in the second quarter. Capstone Asset Management Co. now owns 10,876 shares of the specialty pharmaceutical company’s stock worth $260,000 after buying an additional 530 shares in the last quarter. New York State Teachers Retirement System boosted its stake in AMAG Pharmaceuticals by 42.9% in the second quarter. New York State Teachers Retirement System now owns 20,325 shares of the specialty pharmaceutical company’s stock worth $486,000 after buying an additional 6,100 shares during the period. Falcon Point Capital LLC boosted its stake in AMAG Pharmaceuticals by 86.8% in the second quarter. Falcon Point Capital LLC now owns 711,772 shares of the specialty pharmaceutical company’s stock worth $17,026,000 after buying an additional 330,691 shares during the period. Alps Advisors Inc. boosted its stake in AMAG Pharmaceuticals by 14.2% in the second quarter. Alps Advisors Inc. now owns 65,956 shares of the specialty pharmaceutical company’s stock worth $1,578,000 after buying an additional 8,218 shares during the period. Finally, Capital Fund Management S.A. boosted its stake in AMAG Pharmaceuticals by 8.5% in the second quarter. Capital Fund Management S.A. now owns 20,733 shares of the specialty pharmaceutical company’s stock worth $496,000 after buying an additional 1,622 shares during the period.
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) traded up 2.22% during trading on Friday, reaching $23.00. The company had a trading volume of 1,186,727 shares. The stock has a market capitalization of $786.81 million, a price-to-earnings ratio of 52.87 and a beta of 1.01. AMAG Pharmaceuticals, Inc. has a 52-week low of $17.92 and a 52-week high of $36.83. The stock has a 50 day moving average of $34.15 and a 200 day moving average of $27.42.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, November 3rd. The specialty pharmaceutical company reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.28. The company earned $143.80 million during the quarter, compared to analysts’ expectations of $141.65 million. AMAG Pharmaceuticals had a net margin of 3.12% and a return on equity of 11.10%. The firm’s revenue for the quarter was up 49.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.02 EPS. Equities research analysts forecast that AMAG Pharmaceuticals, Inc. will post $6.00 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece was originally reported by Daily Political and is the propert of of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international trademark and copyright law. The original version of this piece can be read at http://www.dailypolitical.com/2017/01/13/ironwood-investment-management-llc-has-1040000-position-in-amag-pharmaceuticals-inc-amag.html.
A number of analysts have recently commented on AMAG shares. Zacks Investment Research cut AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday. Needham & Company LLC started coverage on AMAG Pharmaceuticals in a research report on Wednesday, October 26th. They set a “buy” rating and a $40.00 target price on the stock. Cantor Fitzgerald started coverage on AMAG Pharmaceuticals in a research report on Thursday, December 15th. They set a “neutral” rating and a $33.00 target price on the stock. Raymond James Financial, Inc. reiterated an “underperform” rating on shares of AMAG Pharmaceuticals in a research report on Monday. Finally, Janney Montgomery Scott cut AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. AMAG Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $35.08.
In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of the company’s stock in a transaction dated Thursday, October 20th. The shares were sold at an average price of $24.80, for a total value of $122,462.40. Following the completion of the transaction, the senior vice president now directly owns 23,668 shares of the company’s stock, valued at approximately $586,966.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 2.30% of the stock is currently owned by company insiders.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.